STAT Plus: This CEO running clinics for Apple and Facebook wants to ‘flip’ the primary care model
It’s been two years since tech behemoth Amazon launched its joint venture in health care…
Category: STAT Plus
STAT Plus: Contract offers unprecedented look at Google deal to obtain patient data from the University of California
SAN FRANCISCO — It was the fall of 2015 when researchers from Google and the…
STAT Plus: An FDA program to ensure decades-old drugs finally get approved is costing billions in price hikes
Back in 2006, the FDA launched an effort to force drug companies to win regulatory…
STAT Plus: College student with disease that causes premature aging is heartened by medical advances
In many ways, Emerson College freshman Meghan Waldron seems like a lot of students in…
STAT Plus: Pharmalittle: Moderna ships first batch of coronavirus vaccine; Mallinckrodt to pay $1.6 billion to settle opioid claims
Hello, everyone, and how are you this morning? We are doing just fine, thank you,…
.jpg)
STAT Plus: ICER, the controversial cost-effectiveness watchdog, reverses course on two migraine drugs
In an unusual move, the Institute for Clinical and Economic Review has reversed course and…
STAT Plus: Google’s labors to anonymize patient data suggest health systems face an uphill battle
Google has been exploring creative ways to protect sensitive health data, even as it has…
STAT Plus: Safety concerns regarding Novartis’s new eye drug boost Regeneron stock
A leading association of eye doctors has warned its members about safety concerns about Novartis’s…
STAT Plus: Nuance begins selling AI system to automate physician note-taking during exams
The medical speech recognition company Nuance said Monday it will begin widely selling an artificial…
STAT Plus: Alkermes sued over death of man who overdosed after taking addiction treatment Vivitrol
The parents of a 26-year-old California man who died of an opioid overdose have sued…
STAT Plus: Pharmalittle: Trump aide wants to bring pharma supply chain home; Walgreens hides prescription errors
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: New partnership tries to make up for missing drug data in cost-effectiveness analyses
The Institute for Clinical and Economic Review, ICER, a nonprofit that has become a central…
STAT Plus: With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption
Months and even years after a successful bone marrow transplant, when patients in remission finally…
STAT Plus: After 21-year journey, Esperion to test market for a cholesterol pill that is less expensive than some competitors
A new cholesterol-lowering medication manufactured by Esperion Therapeutics was approved by the Food and Drug…
Antigen-based metric could better predict which patients benefit from immunotherapy, study says
Immunotherapy has unleashed a revolution in care for some cancer patients. But most immunotherapies help…
STAT Plus: Pharmalittle: Canada may change new rules for drug prices; Trump frustrated over drug pricing
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: In a cramped Kendall Square, biotech startups sublet desks and squeeze into shared labs
Before it launched in January, biotech startup EQRx wasn’t quite large enough to justify leasing…
STAT Plus: Roche confirms departure of gene therapy pioneer Kathy High
Kathy High, a gene therapy pioneer who led the development of a treatment for a…
STAT Plus: Gilead loses another challenge to a pair of U.S. patents for an HIV prevention pill
For the second time this month, Gilead Sciences (GILD) has lost a bid to invalidate…
STAT Plus: Rising out-of-pocket costs for dementia and neuropathy drugs lower patient adherence
As out-of-pocket costs rise for medicines used to treat certain neurologic disorders — such as…
STAT Plus: FDA names genes that may interact with specific drugs, offering clarity to genetic testing industry
The burgeoning industry built around telling patients how their genes may interact with specific drugs…
STAT Plus: Pharmalittle: Need cheap insulin? Try Craigslist; Trump warned about monopolies on coronavirus treatments
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT Plus: Lawmakers to Trump: Don’t give ‘monopolies’ to companies that develop coronavirus treatments with taxpayer funds
Nearly four dozen lawmakers asked the White House to ensure any treatment for the fast-moving…
STAT Plus: Biotech founder who said his painkiller would replace opioids sentenced to 7 years in prison
The founder of a biotech who said his company had developed a painkiller that would…
STAT Plus: European Union proposes independent audits for high-risk AI systems
A version of this story appeared in STAT’s Health Tech newsletter. Click here to subscribe. European regulators…
STAT Plus: Pharmalittle: Prices for active ingredients rise in China due to coronavirus; Grassley presses his drug pricing bill
Top of the morning, and a fine one it is. Warm and sunny skies are…
STAT Plus: Sen. Chuck Grassley takes your questions on drug prices, insulin, and innovation
WASHINGTON — Sen. Chuck Grassley has a clear position on this Congress’s priority list. “You…
STAT Plus: Consumer groups and unions try again to block the AbbVie and Allergan merger
A coalition of consumer groups and unions hopes to convince the Federal Trade Commission to…
STAT Plus: Pharmalittle: Coronavirus clinical trials are going slower than hoped; opioid lawsuit payouts may be less than expected
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: ‘Pharma doesn’t like fish oil’: Wall Street funds sold Amarin after big win with heart drug
Wall Street fund managers lightened their stock positions in Amarin (AMRN) during the fourth quarter…
STAT Plus: Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows
The microbiome industry is on the cusp of a turning point. Seres Therapeutics, one of…
STAT Plus: A city in Georgia is the latest to sue Mallinckrodt over its pricey Acthar Gel medicine
The city of Marietta, Ga., has joined a growing list of unions and local governments…
STAT Plus: Pharmalittle: Generic shortages loom as coronavirus worsens; Connecticut lawmakers look to cap insulin costs
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: A longtime health care investor recalls the insulin bong, praises discipline in valuations, and looks to South America
Les Funtleyder is a longtime health care investor who started his professional investing career just…
STAT Plus: Americans with employer coverage saw growth in drug spending outpace other medical costs
Americans with private employer health insurance spent nearly 26% more on prescription drugs from 2014…
STAT Plus: As opioid crisis intensified, many family doctors found promotional pitches were very good
As the opioid crisis accelerated a decade ago, pharmaceutical sales reps emphasized the benefits of…
STAT Plus: Pharmalittle: India struggles with coronavirus; CVS and Sanofi shake up management
Top of the morning to you, and a fine one, it is. Despite another round…
Opinion: STAT Plus: Why medtech is a different beast than biotech in the life sciences pack
Biotech innovations dominate the life science news cycle — think CRISPR for gene editing or…
STAT Plus: Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins
Amid growing rancor over the cost of insulin, two of the largest manufacturers are objecting…
STAT Plus: Pharmalittle: Big pharma isn’t stepping up to make a coronavirus vaccine; Chinese drug maker threatens Gilead patent
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT Plus: After a new version of a decades-old drug gets orphan status, the price suddenly skyrockets
For years, hospitals and clinics have used an injectable medicine called dehydrated alcohol to treat…
STAT Plus: New life for an old battle: Trump plan to remove tobacco regulation from FDA draws fire
An earlier version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the…
STAT Plus: WHO adviser says an antimicrobial fund can help a market that ‘needs to be fixed’
Over the past month, the World Health Organization and the Access to Medicines Foundation issued…
STAT Plus: Pharmalittle: Trump considers executive action to cut drug prices; feds ‘not done’ with generic price-fixing probe
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT Plus: U.S. biotechs fear the coronavirus outbreak will delay their China-based research
Biotech investors and executives are growing worried that restrictions intended to contain the coronavirus epidemic…
STAT Plus: With new combination drug data, Exelixis takes another shot at prostate cancer treatment
In 2014, the Bay Area biotech company Exelixis (EXEL) tried to develop a drug for…
STAT Plus: Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab
As U.S. regulators consider whether to approve the first new treatment for Alzheimer’s disease in…
STAT Plus: For homebound people and their distant caregivers, smarter speakers to keep track of their health
Every day, Kathleen McVicar of Cotuit, Mass., has a few simple questions for her 85-year-old…
STAT Plus: Pharmalittle: Two more Alzheimer’s drugs fail in studies; how Democratic candidates differ on lowering drug costs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Investor impatience with Gilead reclamation project sparks acquisition chatter
In recent days, there’s been investor chatter about stalled-out Gilead Sciences (GILD) becoming a takeover…